SUPN Earnings Date: Feb 23, 2027 (Estimated) — Supernus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is SUPN's next earnings date?
Supernus Pharmaceuticals, Inc. (SUPN) is expected to report Q4 2026 earnings on Tuesday, February 23, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.02 on revenue of $238.1M.
How did SUPN do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Supernus Pharmaceuticals, Inc. posted EPS of $0.35 versus the $0.49 estimate, a miss of 28.6%. Revenue was $208.6M against a $217.6M estimate.
How much does SUPN stock move after earnings?
SUPN beat EPS estimates in 2 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
🤖 AI Earnings Analysis
Supernus’s S&P SmallCap 600 removal adds a negative index catalyst, while Q3 results were weak: revenue rose 9% to $209M but missed estimates, and EPS of $0.35 fell short by $0.14.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.49 | 0.35 | -28.57% | $208.6M | ❌ Miss | — | — | — |
| 2026-08-03 | Q2 2026 | 0.42 | 0.53 | +26.19% | $219.1M | ✅ Beat | +3.07% | +6.74% | -0.94% |
| 2026-05-05 | Q1 2026 | 0.25 | -0.04 | -116.00% | $207.7M | ❌ Miss | +4.59% | +2.72% | -9.13% |
| 2026-02-24 | Q4 2025 | 0.22 | -0.07 | -131.82% | $211.6M | ❌ Miss | +5.67% | +2.36% | -6.08% |
| 2025-11-04 | Q3 2025 | 0.62 | -0.80 | -229.03% | $192.1M | ❌ Miss | -17.35% | -19.11% | -20.88% |
| 2025-08-05 | Q2 2025 | 0.42 | 0.40 | -4.76% | $180.9M | ❌ Miss | +13.08% | +9.89% | +21.05% |
| 2025-02-25 | Q4 2024 | 0.52 | 0.27 | -48.08% | $174.2M | ❌ Miss | -2.74% | -3.54% | -1.46% |
| 2024-11-04 | Q3 2024 | 0.44 | 0.69 | +56.82% | $175.7M | ✅ Beat | +0.12% | +5.50% | +7.06% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $388.3M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 46.0% | $178.6M | +6.0% | $142.0M | $158.0M | $168.5M | $158.0M |
| Qelbree | 23.4% | $90.8M | +11.6% | $64.7M | $77.5M | $81.4M | $80.9M |
| GOCOVRI | 11.0% | $42.6M | +4.4% | $30.7M | $36.7M | $40.8M | $38.6M |
| Collaboration Revenue | 10.7% | $41.7M | +106.8% | — | — | $20.2M | $32.8M |
| Trokendi Xr | 2.6% | $10.2M | +1.7% | $12.8M | $11.2M | $10.0M | $8.4M |
| Oxtellar X R | 2.0% | $8.0M | -33.8% | $10.2M | $11.6M | $12.0M | $6.8M |
| Royalty, License And Other Revenue | 1.7% | $6.5M | +91.3% | $7.8M | $7.5M | $3.4M | $20.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.